Clinical Trial Update: Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on dovitinib combined with an aromatase inhibitor for metastatic breast cancer; terminated with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Georgetown University | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-09-20